{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:35:04Z","timestamp":1765884904492,"version":"3.48.0"},"reference-count":27,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,1]]},"abstract":"\n Aim:<\/jats:bold>\n Fractional Polynomial (FP) models are widely used in survival analysis for health technology assessment and network meta-analysis (NMA). However, current implementations rely on a fixed set of pre-specified powers, which may constrain model flexibility, limit predictive performance and increase computational cost in Bayesian settings. This study introduces and evaluates a Bayesian FP modeling approach in which the powers are estimated as continuous parameters rather than fixed, aiming to simplify model selection and improve fit.\n Materials & methods:<\/jats:bold>\n Second-order Bayesian FP models were implemented in STAN, allowing the time transformation powers (\n p1<\/jats:italic>\n ,\n p2<\/jats:italic>\n ) to be estimated from the data. Model performance was evaluated across three oncology NMA datasets; in advanced non-small-cell lung cancer, metastatic prostate cancer and early breast cancer. The performance was assessed using visual fit, leave-one-out-information-criteria, root mean square error, incremental survival estimates and computational efficiency. Validation steps included posterior predictive checks, sensitivity analyses and long-term extrapolation.\n Results:<\/jats:bold>\n Across all datasets, variable power models consistently achieved better statistical fit (lower leave-one-out-information-criteria and root mean square error) than fixed power models. Incremental survival estimates were also more stable and clinically plausible, particularly in datasets with complex hazard dynamics. While variable models required slightly more time per run, the approach greatly reduced the number of required model configurations, leading to lower overall computational burden.\n Conclusion:<\/jats:bold>\n Bayesian FP models with variable powers not only improve model fit and simplify model selection but also reduce structural uncertainty by replacing exhaustive grid searches with a unified, data-driven estimation of transformation powers, while retaining interpretability and computational efficiency. By producing robust, well-calibrated survival projections and streamlining model selection, this approach strengthens survival analysis for health technology assessment and supports more reliable decision-making in comparative effectiveness research.\n <\/jats:p>","DOI":"10.57264\/cer-2025-0126","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:36:46Z","timestamp":1765291006000},"source":"Crossref","is-referenced-by-count":0,"title":["Simplifying fractional polynomials in Bayesian network meta-analysis via variable powers"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-0033","authenticated-orcid":false,"given":"Andre","family":"Verhoek","sequence":"first","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario JNM","family":"Ouwens","sequence":"additional","affiliation":[{"name":"Real World Science & Analytics, AstraZeneca Global, V\u00e4sterg\u00f6tland, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-3232","authenticated-orcid":false,"given":"Bart","family":"Heeg","sequence":"additional","affiliation":[{"name":"Cytel, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-9578","authenticated-orcid":false,"given":"Frank GA","family":"Jansman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Deventer Teaching Hospital, Deventer, The Netherlands"},{"name":"Unit of PharmacoTherapy, Epidemiology & -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"Maarten J","family":"Postma","sequence":"additional","affiliation":[{"name":"Unit of Global Health, Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"},{"name":"Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, The Netherlands"},{"name":"Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia"},{"name":"Division of Pharmacology & Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_8_3_2","first-page":"429","article-title":"Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling","volume":"43","author":"Royston P","year":"1994","unstructured":"Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. J. R. Stat. Soc. Ser. C Appl. Stat. 43(3), 429\u2013453 (1994).","journal-title":"J. R. Stat. Soc. Ser. C Appl. Stat."},{"key":"e_1_3_8_4_2","doi-asserted-by":"crossref","DOI":"10.1002\/9780470770771","volume-title":"Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables","author":"Royston P","year":"2008","unstructured":"Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. John Wiley & Sons (2008)."},{"key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen JP","year":"2011","unstructured":"Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med. Res. Methodol. 11, 61 (2011).","journal-title":"BMC Med. Res. Methodol."},{"key":"e_1_3_8_6_2","volume-title":"NICE DSU Technical Support Document 21: Flexible methods for survival analysis","author":"Rutherford MJ","year":"2020","unstructured":"Rutherford MJ, Lambert PC, Sweeting MJ, Pennington R, Crowther MJ, Abrams KR. NICE DSU Technical Support Document 21: Flexible methods for survival analysis. Decision Support Unit, ScHARR, University of Sheffield, UK (2020). Available from: https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/flexible-methods-survival-analysis"},{"key":"e_1_3_8_7_2","unstructured":"NICE Technology Appraisal Guidance 836. Palbociclib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine therapy (2022). Available from: https:\/\/www.nice.org.uk\/guidance\/ta836"},{"key":"e_1_3_8_8_2","unstructured":"NICE Technology Appraisal Guidance 584. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (2019). Available from: https:\/\/www.nice.org.uk\/guidance\/ta584"},{"key":"e_1_3_8_9_2","unstructured":"NICE Technology Appraisal Guidance 463. Cabozantinib for previously treated advanced renal cell carcinoma (2017). Available from: https:\/\/www.nice.org.uk\/guidance\/ta463"},{"key":"e_1_3_8_10_2","unstructured":"NICE Technology Appraisal Guidance 964. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (2024). Available from: https:\/\/www.nice.org.uk\/guidance\/ta964"},{"issue":"3","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"S727","DOI":"10.1016\/j.jval.2019.09.1727","article-title":"PMU109 how do NICE evidence review groups and appraisal committees perceive fractional polynomial methodology in technology appraisals?","volume":"22","author":"Leahy T","year":"2019","unstructured":"Leahy T, Besford M, Sammon C. PMU109 how do NICE evidence review groups and appraisal committees perceive fractional polynomial methodology in technology appraisals? Value Health 22(Suppl. 3), S727 (2019).","journal-title":"Value Health"},{"issue":"12","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.jval.2022.09.1864","article-title":"MSR134 optimizing fractional polynomials by using variable powers","volume":"25","author":"Verhoek A","year":"2022","unstructured":"Verhoek A, Ouwens M, Heeg B. MSR134 optimizing fractional polynomials by using variable powers. Value Health 25(Suppl. 12), S376 (2022).","journal-title":"Value Health"},{"key":"e_1_3_8_13_2","unstructured":"Plummer M. JAGS Version 4.3.0 User Manual (2017). Available from: http:\/\/people.stat.sc.edu\/hansont\/stat740\/jags_user_manual.pdf"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0044"},{"issue":"1","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1016\/j.jval.2021.11.963","article-title":"POSA303 Influence of treatment effect on parameters in fractional polynomials for network meta-analyses","volume":"25","author":"Freigofaite D","year":"2022","unstructured":"Freigofaite D, Verhoek A, Heeg B. POSA303 Influence of treatment effect on parameters in fractional polynomials for network meta-analyses. Value Health 25(Suppl. 1), S198\u2013S199 (2022).","journal-title":"Value Health"},{"key":"e_1_3_8_16_2","unstructured":"Statistics Netherlands. 2025. (Accessed: 30 May 2025). Available from: https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/37360ned\/table"},{"key":"e_1_3_8_17_2","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond MF","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press, UK (2015)."},{"issue":"3","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/bimj.200610328","article-title":"A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation","volume":"49","author":"Sauerbrei W","year":"2007","unstructured":"Sauerbrei W, Royston P, Look M. A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation. Biom. J. 49(3), 453\u2013473 (2007).","journal-title":"Biom. J."},{"key":"e_1_3_8_19_2","unstructured":"Betancourt M. How the shape of a weakly informative prior affects inferences. Stan User's Guide March. (2017). Available from: http:\/\/people.stat.sc.edu\/hansont\/stat740\/jags_user_manual.pdf"},{"key":"e_1_3_8_20_2","unstructured":"Mitchel M Muftakhidinov B Winchen T markummitchell\/engauge-digitizer: Nonrelease (v12.2.1). Zenodo. (2020). https:\/\/doi.org\/10.5281\/zenodo.3941227"},{"key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot P","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 12, 9 (2012).","journal-title":"BMC Med. Res. Methodol."},{"key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.lungcan.2023.01.006","article-title":"Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: a systematic literature review and network meta-analysis","volume":"177","author":"O'Byrne K","year":"2023","unstructured":"O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: a systematic literature review and network meta-analysis. Lung Cancer 177, 11\u201320 (2023).","journal-title":"Lung Cancer"},{"issue":"11","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"Impower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous nsclc","volume":"16","author":"Socinski MA","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM Impower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous nsclc. J. Thoracic Oncol. 16(11), 1909\u20131924 (2021).","journal-title":"J. Thoracic Oncol."},{"issue":"11","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the Phase 3 Keynote-189 study","volume":"41","author":"Garassino MC","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the Phase 3 Keynote-189 study. J. Clin. Oncol. 41(11), 1992\u20131998 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"7","author":"Wang L","year":"2021","unstructured":"Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis. JAMA Oncol. 7(3), 412\u2013420 (2021).","journal-title":"JAMA Oncol."},{"issue":"5","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses","volume":"205","author":"Armstrong AJ","year":"2021","unstructured":"Armstrong AJ, Shore ND, Szmulewitz RZ Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES post hoc analyses. J. Urol. 205(5), 1361\u20131371 (2021).","journal-title":"J. Urol."},{"issue":"1","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13643-017-0588-2","article-title":"Herceptin\u00ae (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis","volume":"6","author":"Wilson FR","year":"2017","unstructured":"Wilson FR, Coombes ME, Wylie Q Herceptin\u00ae (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. Syst. Rev. 6(1), 196 (2017).","journal-title":"Syst. Rev."},{"issue":"33","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-mg\/Keynote-054 trial","volume":"38","author":"Koornstra R","year":"2020","unstructured":"Koornstra R, Hernandez-Aya L, Di Giacomo AM Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-mg\/Keynote-054 trial. J. Clin. Oncol. 38(33), 3925\u20133936 (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s11222-016-9696-4","article-title":"Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC","volume":"27","author":"Vehtari A","year":"2017","unstructured":"Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat. Comput. 27, 1413\u20131432 (2017).","journal-title":"Stat. Comput."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:30:30Z","timestamp":1765884630000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.57264\/cer-2025-0126"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0126","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e250126"}}